Neogap Therapeutics appoints Jonas Mattson to its board of directors
Ella Day | August 26, 2025 | Appointment | Research and Development | Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors
Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment supports the company’s drive to strengthen its structure for continued clinical and strategic development and advance its first clinical programme.
Mattsson has extensive expertise from both clinical and academic practice. He is currently director of the Hans Messner Allogeneic Transplant Programme at Princess Margaret Cancer Centre in Toronto and professor of medicine at the University of Toronto. Previously, he was professor at Karolinska Institutet and senior consultant at Karolinska University Hospital, both in Solna, Sweden, and Oslo University Hospital, Norway. He also holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, established as the world’s first professorship in cell therapy.
“Neogap’s therapy creates a targeted treatment with the potential to cure patients who currently have no remaining treatment options. I look forward to contributing to the company’s continued development,” says Jonas Mattsson.
“Jonas brings clinical expertise and an international perspective with deep roots in advanced cell therapy. His experience will be of great value as we progress in our clinical development programme and strengthen the company for the next stages,” says Samuel Svensson, CEO of Neogap Therapeutics.
Neogap is developing cancer immunotherapy using patient’s own cells and its technologies PIOR and EpiTCer. The company is located at the Cancer Center Karolinska, in Stockholm, Sweden.
Ella Day
26/8/25
Related Content
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme …
Neogap chosen for Innovate Nordics 2025 Acceleration Programme
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics’ 2025 acceleration programme, …
Allergan shareholders reject proposal to split roles of chairman and CEO
Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, …
